@misc{10498/27140,
year = {2022},
month = {5},
url = {http://hdl.handle.net/10498/27140},
abstract = {This retrospective study evaluated 66 patients diagnosed with relapsed and/or refractory mantle cell lymphoma (R/R MCL)
treated with ibrutinib in Spain in routine clinical practice. At diagnosis, patients had a median age of 64.5 years, 63.6% presented
with intermediate/high sMIPI (simplified prognostic index for advanced-stage mantle cell lymphoma), 24.5% had the
blastoid variant, and 55.6% had a Ki67 > 30%. Patients had received a median of 2 prior lines of therapy (range 1–2; min–max
1–7). Overall response rate was 63.5%, with 38.1% of patients achieving complete response (CR). With a median duration of
ibrutinib exposure of 10.7 months (range 5.2–19.6; min–max 0.3–36), the median progression-free survival (PFS) and overall
survival (OS) were 20 months [95% confidence interval (CI) 8.8–31.1] and 32 months (95% CI 22.6–41.3), respectively, and
were not reached in patients achieving CR. No grade ≥ 3 cardiovascular toxicity or bleeding was reported. This study supports
that treatment with ibrutinib leads to high response rates and favorable survival outcomes in patients with R/R MCL.},
publisher = {SPRINGER},
keywords = {Mantle-cell lymphoma},
keywords = {Relapsed/refractory},
keywords = {Ibrutinib},
keywords = {Clinical practice},
keywords = {Real-world evidence},
title = {IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice},
doi = {10.1007/S12185-022-03367-Z},
author = {Sancho, Juan-Manuel and Marín‑Niebla, Ana and Fernández, Silvia and Capote Huelva, Francisco Javier and Cañigral, Carolina and Grande, Carlos and Donato, Eva and Zeberio, Izaskun and Puerta, Jose-Manuel and Rivas, Alfredo and Pérez‑Ceballos, Elena and Vale, Ana and García‑Sancho, Alejandro Martín and Salar, Antonio and González‑Barca, Eva and Teruel, Anabel and Pastoriza, Carmen and Conde‑Royo, Diego and Sánchez‑García, Joaquín and Barrenetxea, Cristina and Arranz, Reyes and Hernández‑Rivas, Jose-Angel and Ramírez, María‑José and Jiménez, Aroa and Rubio‑Azpeitia, Eva},
}